The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II study (NCI9775) of sapanisertib (MLN0128/TAK-228) in relapsed and/or refractory acute lymphoblastic leukemia (ALL): Interim analysis.
 
Aref Al-Kali
Research Funding - Ambit BioSciences (Inst); Astex Pharmaceuticals (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); H3 Biomedicine (Inst); MedImmune (Inst); Novartis (Inst); Onconova Therapeutics (Inst)
 
Ibrahim Aldoss
Speakers' Bureau - Jazz Pharmaceuticals
 
Carrie Strand
No Relationships to Disclose
 
Bijal D. Shah
Honoraria - Pharmacyclics/Janssen
Consulting or Advisory Role - Adaptive Biotechnologies
Research Funding - Incyte; Jazz Pharmaceuticals (Inst)
 
Jonathan Allen Webster
No Relationships to Disclose
 
Bhavana Bhatnagar
No Relationships to Disclose
 
Mojtaba Akhtari
No Relationships to Disclose
 
L. Austin Doyle
Patents, Royalties, Other Intellectual Property - I receive royalties for a patent related to cloning and characterizing the ABCG2 transporter. This patent is administered through the University of Maryland School of Medicine. The patent has nothing to do with my current work or any work in ASCO abstrac
 
Scott H. Kaufmann
No Relationships to Disclose